MP39-13 COST-EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY REGIMENS PRIOR TO RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER. (May 2022)